Mahamaya Lifesciences Ltd
- Market Cap ₹ 267 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 51.3
- Book Value ₹
- Dividend Yield %
- ROCE 21.1 %
- ROE 23.6 %
- Face Value ₹ 10.0
Pros
Cons
- Debtor days have increased from 42.2 to 64.0 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 90 | 137 | 161 | |
| 84 | 128 | 148 | |
| Operating Profit | 6 | 9 | 13 |
| OPM % | 7% | 6% | 8% |
| 0 | 0 | 1 | |
| Interest | 2 | 3 | 6 |
| Depreciation | 1 | 1 | 1 |
| Profit before tax | 4 | 5 | 7 |
| Tax % | 27% | 26% | 27% |
| 3 | 4 | 5 | |
| EPS in Rs | |||
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 39% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 24% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 1 | 1 | 1 |
| Reserves | 14 | 18 | 23 |
| 19 | 24 | 55 | |
| 21 | 34 | 33 | |
| Total Liabilities | 56 | 78 | 112 |
| 20 | 21 | 21 | |
| CWIP | 2 | 2 | 3 |
| Investments | 0 | 0 | 0 |
| 34 | 54 | 88 | |
| Total Assets | 56 | 78 | 112 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 37 | 25 | 64 |
| Inventory Days | 93 | 109 | 137 |
| Days Payable | 83 | 87 | 61 |
| Cash Conversion Cycle | 47 | 48 | 140 |
| Working Capital Days | 8 | 9 | 14 |
| ROCE % | 20% | 21% |
Documents
Annual reports
No data available.